Boothbay Fund Management, LLC Cyma Bay Therapeutics, Inc. Transaction History

Boothbay Fund Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$10.86 - $17.62 $234,380 - $380,274	21,582 New	21,582 $321,000
Q1 2023 May 15, 2023	SELL	$5.88 - $9.59 $10,713 - $17,472	-1,822 Reduced 10.08%	16,249 $141,000
Q4 2022 Feb 14, 2023	BUY	$3.22 - $6.27 $58,188 - $113,305	18,071 New	18,071 $113,000
Q2 2022 Aug 15, 2022	BUY	$1.72 - $3.39 $24,903 - $49,083	14,479 New	14,479 $43,000
Q3 2020 Nov 16, 2020	SELL	$3.32 - $7.24 $529,423 - $1.15 Million	-159,465 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$1.41 - $4.25 $77,509 - $233,626	-54,971 Reduced 25.64%	159,465 $557,000
Q1 2020 May 15, 2020	BUY	$1.25 - $2.02 $268,045 - $433,160	214,436 New	214,436 $317,000
Q4 2019 Feb 14, 2020	SELL	$1.33 - $5.93 $35,630 - $158,864	-26,790 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$5.12 - $7.21 $137,164 - $193,155	26,790 New	26,790 $137,000
Q4 2017 Feb 14, 2018	SELL	$7.67 - $9.31 $384,090 - $466,216	-50,077 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$5.95 - $8.26 $297,958 - $413,636	50,077	50,077 $404,000

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Boothbay Fund Management, LLC with notifications on news.